PriceTargets.com logo

Lineage Cell Therapeutics - LCTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.25
  • Forecasted Upside: 840.86%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.56 As of 12/20/2024 06:45 PM ET
▲ +0.056 (11.16%)

This chart shows the closing price for LCTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lineage Cell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LCTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LCTX

Analyst Price Target is $5.25
▲ +840.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Lineage Cell Therapeutics in the last 3 months. The average price target is $5.25, with a high forecast of $9.00 and a low forecast of $2.00. The average price target represents a 840.86% upside from the last price of $0.56.

This chart shows the closing price for LCTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Lineage Cell Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2024HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $9.00
11/20/2024D. Boral CapitalLower TargetBuy ➝ Buy$3.00 ➝ $2.00
8/20/2024Craig HallumInitiated CoverageBuy$4.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
2/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00
7/25/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.00
7/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/10/2023HC WainwrightReiterated RatingBuy$7.00
11/1/2022Robert W. BairdInitiated CoverageOutperform$5.00
6/14/2022B. RileyInitiated CoverageBuy$4.00
5/13/2022Maxim GroupReiterated RatingBuy$5.00
3/11/2022Dawson JamesReiterated RatingBuy$6.00
3/11/2022HC WainwrightReiterated RatingBuy$7.00
10/4/2021Noble FinancialReiterated RatingBuy$8.00
10/1/2021HC WainwrightReiterated RatingBuy$7.00
9/16/2021HC WainwrightReiterated RatingBuy$7.00
9/16/2021Noble FinancialReiterated RatingBuy$8.00
8/19/2021Noble FinancialInitiated CoverageOutperform$8.00
4/7/2021Chardan CapitalReiterated RatingBuy$4.00
3/30/2021Cantor FitzgeraldInitiated CoverageOverweight$6.00
3/12/2021Maxim GroupReiterated RatingBuy$5.00
2/24/2021HC WainwrightReiterated RatingBuy$7.00
10/12/2020Dawson JamesReiterated RatingBuy$6.00
9/17/2020Noble FinancialInitiated CoverageOutperform
9/2/2020HC WainwrightReiterated RatingBuy
8/7/2020Maxim GroupInitiated CoverageBuy$3.00
6/26/2020Maxim GroupInitiated CoverageBuy$3.00
6/10/2020HC WainwrightReiterated RatingBuy
6/2/2020Maxim GroupReiterated RatingBuy$3.00
5/12/2020Chardan CapitalReiterated RatingBuy
5/9/2020Maxim GroupInitiated CoverageBuy$3.00
5/5/2020HC WainwrightReiterated RatingBuy$4.00
3/13/2020HC WainwrightReiterated RatingBuy
2/10/2020HC WainwrightReiterated RatingBuy$4.00
1/3/2020HC WainwrightReiterated RatingBuy$4.00
(Data available from 12/23/2019 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Lineage Cell Therapeutics logo
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $0.56
Low: $0.51
High: $0.56

50 Day Range

MA: N/A

52 Week Range

Now: $0.56
Low: $0.48
High: $1.61

Volume

2,140,050 shs

Average Volume

1,071,892 shs

Market Capitalization

$122.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Lineage Cell Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Lineage Cell Therapeutics in the last year: Cantor Fitzgerald, Craig Hallum, D. Boral Capital, and HC Wainwright.
View the latest analyst ratings for LCTX.

What is the current price target for Lineage Cell Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Lineage Cell Therapeutics in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 840.9%. HC Wainwright has the highest price target set, predicting LCTX will reach $9.00 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $2.00 for Lineage Cell Therapeutics in the next year.
View the latest price targets for LCTX.

What is the current consensus analyst rating for Lineage Cell Therapeutics?

Lineage Cell Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LCTX will outperform the market and that investors should add to their positions of Lineage Cell Therapeutics.
View the latest ratings for LCTX.

What other companies compete with Lineage Cell Therapeutics?

Other companies that are similar to Lineage Cell Therapeutics include Zevra Therapeutics, Verve Therapeutics, Corvus Pharmaceuticals, SIGA Technologies and Arcturus Therapeutics. Learn More about companies similar to Lineage Cell Therapeutics.

How do I contact Lineage Cell Therapeutics' investor relations team?

Lineage Cell Therapeutics' physical mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company's listed phone number is (442) 287-8963 and its investor relations email address is [email protected]. The official website for Lineage Cell Therapeutics is www.lineagecell.com. Learn More about contacing Lineage Cell Therapeutics investor relations.